A venture capital firm based in Hong Kong makes seed and early stage investments across several sectors including the life sciences. The firm typically allocates USD 75K to 500K per company as well as possible continuation into Series A. The firm can invest globally and is actively seeking new investment opportunities.

In the life sciences, the firm is interested in DNA genetic testing. For example, technologies such as pre-natal testing and DNA testing for oncology screening. The firm is also interested in and health & wellness technology for preventive care or management of chronic illness such as diabetes. The firm will focus on startups that have already gained some traction. The firm historically invested in molecular diagnostics and DNA screening.

The firm looks to partner with exceptional entrepreneurs and generally looks to take a board seat post investment, though this is not a requirement.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm based in the United Kingdom seeks to invest in companies that need capital within the range of £1m to £10m with a typical investment size at £3 million per company. The firm focuses on investments in life science companies at clinical or growth stage. The firm has a syndicated fund of £100 million, and seeks to make 1-2 new investments within the next year in addition to their current portfolio of 8 active companies. The firm typically leads investments, though will co-invest depending on the opportunity. The firm focuses on UK-based private companies, though is open to companies based in Europe and the U.S.

The firm is currently looking for new opportunities in the Medical Technology and Therapeutics sectors. The firm will also consider diagnostics companies, depending on the opportunity. For therapeutics, the firm will invest in both small molecules and biologics. The firm will consider all classes of medical devices, and prefers to invest in devices with a regulatory pathway. The firm invests in clinical-stage to commercialized products, and prefers clinical-stage technology with a clear path towards revenue.

The firm focuses on private companies and prefers companies with a strong management team and significant growth potential that are able to deliver returns for investors within a 3 to 5-year timetable. The firm looks to take a board seat post investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm based in the central US is currently in the process of raising its 2nd fund, targeted at $50 million. The firm typically makes equity co-investments in seed and early stage companies ranging from $50,000 to $8 million with most investments in the $250,000 to $1.5 million range. The firm typically makes 6-8 allocations per year, and is open to opportunities throughout the United States and Canada.

The firm is looking for companies in telemedicine, healthcare IT, pathology, diagnostics, bioinformatics, medical devices, and healthcare automation. The firm does not look at pharmaceutical opportunities. The firm is interested in early stage companies from pre-prototype or pre-clinical to clinical stage that have a cost efficient and innovative product with a clear pathway to exit in approximately 3-5 years. The firm is open to consider all indications and types of devices. The firm is not interested in late stage investments into companies that already have a product on the market. The firm focuses on opportunities that focus on patient care improvements, healthcare IT or products that solve critical problems that hospitals, doctors or patients face—and for which the company can receive reimbursement.

The firm is looking for entrepreneur-based management teams with experience who are open to work with them. The firm looks to take a board seat following investment. In addition to capital, the firm is capable of providing strategic mentoring as well as incubation services both locally and remotely in areas of HR, Marketing, Accounting and Software Development.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

An investment firm with offices in the USA and Europe manages focused private equity funds for family offices and high-net worth individuals. The firm seeks to transform SMEs with local traction to global front-runners. Their typical investment size is $1 M – 20 M. They are looking to make 4 new investments in the next year, and are currently focused on OTM medical technology.

The firm is opportunistic and will consider deals across the life sciences board, but is currently focused on medical technology, industrial processes, materials, HCIT and digital health with high tech underpinnings, and food production, distribution, and transformation.

The firm desires an experienced, passionate team of entrepreneurs with international experience, capable of building a fast growing global business. They do not invest in start ups. They look to acquire 20-80% equity in SME’s with $3-5 M in revenue, or fast growing companies that will be generating revenue within a year with all regulatory barriers cleared. They require a clear, scalable path to globalization. The firm pursues a 60-day due diligence period when considering a deal.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A joint venture investment company backed by two large corporations is investing in healthcare from a $100 million fund. The firm strives to catalyze the success of digital medicine products, services and business models by investing in early-stage companies. The firm prefers to co-invest and makes equity investments of up to $5 million per deal. The firm is currently seeking opportunities in the US, EU, and Israel.

The firm is seeking entrepreneurs using digital technology to transform pharmaceutical products, sales and marketing, R&D, and enterprise operations. The firm also considers personalized medicine using -omics science. Examples may include enterprise software solutions that improves clinical care or mobile sensors for disease management in home care settings. The firm is less interested in consumer products. The firm is seeking products with some market traction or credible customers.

The firm works with strong founders who demonstrate full understanding of their market sector.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A fund backed entirely by a consortium of Senior Living Systems looks to allocate anywhere from $.5 – $5 million into commercial stage companies with products or services for the aging and elderly population, typically in a series A, B or C round. The firm has the majority of its portfolio dedicated to companies based in the US although they do have the ability to invest internationally as well. The firm could make as many as 4-5 investments over the next 6-12 months.

The firm is looking for companies operating in the Healthcare IT and Services sectors, with products or services for the aging and elderly population. The firm is only interested in investing in companies with products already on the market that have been able to demonstrate some market traction prior to investment.

The firm is looking for privately held companies with experienced management teams. The firm prefers there to be a complete management team in place prior to investment and often looks to take a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com